Genticel SA, of Toulouse, France, reported 12-month data from its phase II study of immunotherapeutic candidate GTL001, which is designed to clear human papillomavirus (HPV) 16 and/or 18 infection, showing clear statistical separation (p=0.018) in the predefined subgroup of patients with normal cytology, which comprises about 75 percent in GTL001's target population.